Form 8-K - Current report:
SEC Accession No. 0001628280-26-023222
Filing Date
2026-04-02
Accepted
2026-04-02 16:30:32
Documents
11
Period of Report
2026-03-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20260329.htm   iXBRL 8-K 26446
  Complete submission text file 0001628280-26-023222.txt   144293

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20260329.xsd EX-101.SCH 1834
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20260329_lab.xml EX-101.LAB 22548
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20260329_pre.xml EX-101.PRE 13084
14 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20260329_htm.xml XML 2834
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 26834251
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)